资源类型

期刊论文 140

年份

2024 4

2023 24

2022 26

2021 30

2020 46

2019 3

2015 1

2010 1

2008 1

展开 ︾

关键词

COVID-19 14

新冠病毒肺炎 12

SARS-CoV-2 5

新型冠状病毒肺炎 5

临床特征 3

肺炎 3

中药 2

保持社交距离 2

口罩 2

合并症 2

大流行 2

抗病毒 2

新型冠状病毒肺炎（COVID-19） 2

疫苗接种 2

集中隔离 2

2019-nCoV 1

N-糖基化 1

CAR19 1

CART19 1

展开 ︾

检索范围：

排序： 展示方式：

Innovation-driven trend shaping COVID-19 vaccine development in China

《医学前沿（英文）》 2023年 第17卷 第6期   页码 1096-1116 doi: 10.1007/s11684-023-1034-6

摘要： Confronted with the coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized. Likewise, new technologies may provide more potent or broader immunity and will contribute to fight against hypermutated SARS-CoV-2 variants. All in all, with the ultimate aim of delivering robust and durable protection that is resilient to emerging infectious disease, alongside the traditional routes, the discovery of innovative approach to developing effective vaccines based on virus properties remains our top priority.

关键词： SARS-CoV-2     COVID-19 vaccine     vaccine development    

HTML PDF 收藏

A review of the safety and efficacy of current COVID-19 vaccines

《医学前沿（英文）》 2022年 第16卷 第1期   页码 39-55 doi: 10.1007/s11684-021-0893-y

摘要： Vaccination is the most effective and feasible way to contain the coronavirus disease 2019 (COVID-19) pandemic. The rapid development of effective COVID-19 vaccines is an extraordinary achievement. This study reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressed COVID-19 vaccines and discussed the challenges and prospects of the vaccine-based approaches in a global crisis. Overall, most of the current vaccines have shown safety and efficacy/effectiveness during actual clinical trials or in the real-world studies, indicating a development of pandemic control. However, many challenges are faced by pandemic control in terms of maximizing the effect of vaccines, such as rapid vaccine coverage, strategies to address variants with immune escape capability, and surveillance of vaccine safety in the medium- and long-terms.

关键词： COVID-19     SARS-CoV-2     vaccine     safety     efficacy     effectiveness     immunogenicity    

HTML PDF 收藏

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

《医学前沿（英文）》 2022年 第16卷 第2期   页码 185-195 doi: 10.1007/s11684-021-0913-y

摘要： The record speed at which Chinese scientists identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and shared its genomic sequence with the world, has greatly facilitated the development of coronavirus disease (COVID-19) diagnostics, drugs, and vaccines. It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year, due to the efforts of the scientific community, biopharmaceutical industry, and regulatory agencies worldwide. The challenges are both great and multidimensional due to the rapid emergence of virus variants and waning of vaccine immunity. Vaccination strategies need to adapt to these challenges to keep population immunity above the herd immunity threshold, by increasing vaccine coverage, especially for older adults and young people, and providing timely booster doses with homologous or heterologous vaccine boosts. Further research should be undertaken to develop more effective vaccines against SARS-CoV-2 variants and to understand the best prime-boost vaccine combinations and immunization strategies to provide sufficient and sustainable immune protection against COVID-19.

关键词： COVID-19     pandemics     SARS-CoV-2     vaccination    

HTML PDF 收藏

COVID-19: why not learn from the past?

《医学前沿（英文）》 2021年 第15卷 第5期   页码 776-781 doi: 10.1007/s11684-021-0883-0

HTML PDF 收藏

Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy

《医学前沿（英文）》 2024年 第18卷 第1期   页码 19-30 doi: 10.1007/s11684-024-1074-6

摘要： The pneumonia caused by novel coronavirus SARS-CoV-2 infection in early December 2019, which was later named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), rapidly spread across the world. China has made extraordinary efforts to this unprecedented pandemic, put its response and control at a very high level of infectious disease management (Category B but with measures for Category A), given top priority to the people and their lives, and balanced the pandemic control and socio-economic development. After more than three years’ fighting against this disease, China downgraded the management of COVID-19 to Category B infectious disease on January 8, 2023 and the WHO declared the end of public health emergency on May 5, 2023. However, the ending of pandemic does not mean that the disease is no longer a health threat. Experiences against COVID-19 from China and the whole world should be learned to prepare well for the future public health emergencies. This article gives a systematic review of the trajectory of COVID-19 development in China, summarizes the critical policy arrangements and provides evidence for the adjustment during policy making process, so as to share experiences with international community and contribute to the global health for all humanity.

关键词： COVID-19     public health     response and control strategy     science-based policy making    

HTML PDF 收藏

Emergence of SARS and COVID-19 and preparedness for the next emerging disease X

《医学前沿（英文）》 2024年 第18卷 第1期   页码 1-18 doi: 10.1007/s11684-024-1066-6

摘要： Severe acute respiratory syndrome (SARS) and coronavirus disease 2019 (COVID-19) are two human coronavirus diseases emerging in this century, posing tremendous threats to public health and causing great loss to lives and economy. In this review, we retrospect the studies tracing the molecular evolution of SARS-CoV, and we sort out current research findings about the potential ancestor of SARS-CoV-2. Updated knowledge about SARS-CoV-2-like viruses found in wildlife, the animal susceptibility to SARS-CoV-2, as well as the interspecies transmission risk of SARS-related coronaviruses (SARSr-CoVs) are gathered here. Finally, we discuss the strategies of how to be prepared against future outbreaks of emerging or re-emerging coronaviruses.

关键词： SARS     COVID-19     coronavirus    

HTML PDF 收藏

Repercussions of COVID-19 pandemic on solid waste generation and management strategies

《环境科学与工程前沿（英文）》 2021年 第15卷 第6期 doi: 10.1007/s11783-021-1407-5

摘要：

• Implication of COVID-19 on medical waste and MSW generation is studied.

关键词： COVID-19     Medical waste     Personal protective equipment     Municipal solid waste     Waste management    

HTML PDF 收藏

Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center

《医学前沿（英文）》 2022年 第16卷 第1期   页码 111-125 doi: 10.1007/s11684-021-0854-5

摘要： The coronavirus disease 2019 (COVID-19) has spread globally. Although mixed liver impairment has been reported in COVID-19 patients, the association of liver injury caused by specific subtype especially chronic hepatitis B (CHB) with COVID-19 has not been elucidated. In this multi-center, retrospective, and observational cohort study, 109 CHB and 327 non-CHB patients with COVID-19 were propensity score matched at an approximate ratio of 3:1 on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, disease severity, and clinical outcomes were compared. Furthermore, univariable and multivariable logistic and Cox regression models were used to explore the risk factors for disease severity and mortality, respectively. A higher proportion of CHB patients (30 of 109 (27.52%)) developed into severe status than non-CHB patients (17 of 327 (5.20%)). In addition to previously reported liver impairment markers, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin, we identified several novel risk factors including elevated lactate dehydrogenase (≥245 U/L, hazard ratio (HR) = 8.639, 95% confidence interval (CI) = 2.528–29.523; P <0.001) and coagulation-related biomarker D-dimer (≥0.5 μg/mL, HR= 4.321, 95% CI= 1.443–12.939; P = 0.009) and decreased albumin (<35 g/L, HR= 0.131, 95% CI= 0.048–0.361; P <0.001) and albumin/globulin ratio (<1.5, HR= 0.123, 95% CI= 0.017–0.918; P = 0.041). In conclusion, COVID-19 patients with CHB were more likely to develop into severe illness and die. The risk factors that we identified may be helpful for early clinical surveillance of critical progression.

关键词： COVID-19     chronic hepatitis B     liver injury     coagulation dysfunction    

HTML PDF 收藏

Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant

《医学前沿（英文）》 2023年 第17卷 第3期   页码 576-580 doi: 10.1007/s11684-023-0991-0

摘要： Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant

关键词： variant    

HTML PDF 收藏

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak

《医学前沿（英文）》 2023年 第17卷 第3期   页码 562-575 doi: 10.1007/s11684-022-0977-3

摘要： The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. Compared to an earlier patient cohort infected by SARS-CoV-2 prototype strains in 2020, BA.2.2 infection led to distinct fluctuations of pathophysiological markers in the peripheral blood. In particular, severe/critical cases of COVID-19 post BA.2.2 infection were associated with less pro-inflammatory macrophage activation and stronger interferon alpha response in the bronchoalveolar microenvironment. Importantly, the abnormal biomarkers were significantly subdued in individuals who had been immunized by 2 or 3 doses of SARS-CoV-2 prototype-inactivated vaccines, supporting the estimation of an overall 96.02% of protection rate against severe/critical disease in the 4854 cases in our BA.2.2 patient cohort with traceable vaccination records. Furthermore, even though age was a critical risk factor of the severity of COVID-19 post BA.2.2 infection, vaccination-elicited protection against severe/critical COVID-19 reached 90.15% in patients aged ≥ 60 years old. Together, our study delineates the pathophysiological features of Omicron BA.2.2 sublineages and demonstrates significant protection conferred by prior prototype-based inactivated vaccines.

关键词： SARS-CoV-2     COVID-19     host response     bronchoalveolar lavage fluid (BALF)    

HTML PDF 收藏

Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine

《医学前沿（英文）》 doi: 10.1007/s11684-023-1054-2

摘要： Corona virus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected the whole world. Acquired thrombotic thrombocytopenic purpura (TTP) has been reported after administration of mRNA- or adenoviral vector-based COVID-19 vaccines, including Ad26.COV2-S, BNT162b2, mRNA-1273, and ChAdOx1 nCov-19. However, whether inactivated vaccines, such as CoronaVac, could cause TTP and whether the symptoms in TTPs caused by inactivated vaccines are different from previously reported cases are unknown. In this study, two cases were reported. Both cases developed TTP after the second CoronaVac vaccination shot, but not the first. They demonstrated symptoms of fever, neurological abnormalities, renal dysfunction, thrombocytopenia, and hemolysis. Both patients achieved complete remission through several sessions of plasma exchanges and immune suppression. The incidence of TTP in Nanjing area was analyzed. The number of patients with TTP was 12 in 2019, 6 in 2020, 16 in 2021, and 19 in 2022. To the authors’ knowledge, this report is the first report of TTP associated with inactivated COVID-19 vaccine (CoronaVac). The rarity and delayed onset may be due to the relatively milder immune response caused by the inactivated vaccines than mRNA-based ones. Timely plasma exchange is a vital treatment for CoronaVac-related TTP, similar to activated vaccine-related TTP.

关键词： thrombotic thrombocytopenia purpura (TTP)     corona virus disease 2019 (COVID-19)     CoronaVac     acute respiratory syndrome coronavirus 2 (SARS-CoV-2)     vaccine    

HTML PDF 收藏

Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic

《医学前沿（英文）》 2022年 第16卷 第6期   页码 984-990 doi: 10.1007/s11684-022-0930-5

摘要： Nonpharmaceutical interventions (NPIs) have been commonly deployed to prevent and control the spread of the coronavirus disease 2019 (COVID-19), resulting in a worldwide decline in influenza prevalence. However, the influenza risk in China warrants cautious assessment. We conducted a cross-sectional, sero-epidemiological study in Shandong Province, Northern China in mid-2021. Hemagglutination inhibition was performed to test antibodies against four influenza vaccine strains. A combination of descriptive and meta-analyses was adopted to compare the seroprevalence of influenza antibodies before and during the COVID-19 pandemic. The overall seroprevalence values against A/H1N1pdm09, A/H3N2, B/Victoria, and B/Yamagata were 17.8% (95% CI 16.2%–19.5%), 23.5% (95% CI 21.7%–25.4%), 7.6% (95% CI 6.6%–8.7%), and 15.0 (95% CI 13.5%–16.5%), respectively, in the study period. The overall vaccination rate was extremely low (2.6%). Our results revealed that antibody titers in vaccinated participants were significantly higher than those in unvaccinated individuals (P < 0.001). Notably, the meta-analysis showed that antibodies against A/H1N1pdm09 and A/H3N2 were significantly low in adults after the COVID-19 pandemic ( P < 0.01). Increasing vaccination rates and maintaining NPIs are recommended to prevent an elevated influenza risk in China.

关键词： influenza virus     seroprevalence     antibody     COVID-19     cross-sectional study    

HTML PDF 收藏

Application of wastewater-based epidemiological monitoring of COVID-19 for disease surveillance in the

《环境科学与工程前沿（英文）》 doi: 10.1007/s11783-024-1858-6

摘要：

● A continuous wastewater-based monitoring of SARS-CoV-2 was conducted.

关键词： Wastewater-based epidemiology     Monitoring     COVID-19     Post-epidemic era    

HTML PDF 收藏

Can we migrate COVID-19 spreading risk?

Qingyan Chen

《环境科学与工程前沿（英文）》 2021年 第15卷 第3期 doi: 10.1007/s11783-020-1328-8

摘要： Abstract It is well recognized that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus could be spread through touch and large droplets. However, we may have under-estimated the disease transmission by small droplets or aerosols that contain SARS-CoV-2 virus. Social distancing in public transport vehicles, such as airplanes, is not feasible. It is also not possible to wear masks in restaurant. This paper recommended wearing masks in airplanes and use partition screens in the middle of a table in a restaurant to reduce the infection caused by SARS-CoV-2 virus. Advanced ventilation systems, such as personalized ventilation and displacement ventilation, are strongly recommended for transport vehicles and buildings.

关键词： Airborne transmission     Ventilation     Masks     Partitions    

HTML PDF 收藏

Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19-19 in Wuhan

Li Ni, Ling Zhou, Min Zhou, Jianping Zhao, Dao Wen Wang

《医学前沿（英文）》 2020年 第14卷 第2期   页码 210-214 doi: 10.1007/s11684-020-0757-x

摘要： In December 2019, an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ~2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.

关键词： novel coronavirus (2019-nCoV)     COVID-19     Chinese traditional patent medicine     Shuanghuanglian oral liquid    

HTML PDF 收藏

标题 作者 时间 类型 操作

Innovation-driven trend shaping COVID-19 vaccine development in China

期刊论文

A review of the safety and efficacy of current COVID-19 vaccines

期刊论文

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

期刊论文

COVID-19: why not learn from the past?

期刊论文

Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy

期刊论文

Emergence of SARS and COVID-19 and preparedness for the next emerging disease X

期刊论文

Repercussions of COVID-19 pandemic on solid waste generation and management strategies

期刊论文

Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center

期刊论文

Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant

期刊论文

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak

期刊论文

Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine

期刊论文

Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic

期刊论文

Application of wastewater-based epidemiological monitoring of COVID-19 for disease surveillance in the

期刊论文

Can we migrate COVID-19 spreading risk?

Qingyan Chen

期刊论文

Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19-19 in Wuhan

Li Ni, Ling Zhou, Min Zhou, Jianping Zhao, Dao Wen Wang

期刊论文